Press release content from Globe Newswire. The AP news staff was not involved in its creation.
goeasy Ltd. Reports Record Results for the Fourth Quarter and Full Year
goeasy Ltd.February 17, 2021 GMT
Loan Portfolio of $1.25 billion, up 12% Adjusted Quarterly Diluted Earnings per Share of $2.24, up 55% Adjusted Annual Net Income of $118 million, up 47% Adjusted Annual Diluted Earnings per Share of $7.57, up 46% Annual Dividend per Share Increased to $2.64, up 47%
MISSISSAUGA, Ontario, Feb. 17, 2021 (GLOBE NEWSWIRE)
goeasy Ltd. (TSX: GSY), (“
goeasy ” or the “Company”), a leading full-service provider of goods and alternative financial services, announced its results for the fourth quarter and full year ended December 31, 2020.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
BC Craft Supply Co. Secures 45kg of High THC Flower from Canada’s First Licensed Micro Cultivator
BC Craft Supply Co. Ltd.February 18, 2021 GMT
VANCOUVER, British Columbia, Feb. 18, 2021 (GLOBE NEWSWIRE) BC Craft Supply Co. Ltd. (the “Company” or “BC Craft”) (CSE:CRFT) (FSE:ZZD1) is pleased to announce a new product into its supply chain grown by Canada’s first licensed micro cultivator, Canandia. 45kg of Death Bubba has been purchased by BC Craft and shipped to Indiva Limited (“Indiva”) (TSXV:NDVA) (OTCQX:NDVAF) for processing into Indiva’s new premium brand, Artisan Batch. The large craft buds are processed into sleek 3.5 gram jars which are now available in BC through private and provincial retailers. Death Bubba is an indica-dominant hybrid grown in live soil and nourished with filtered water; its frosty lime green buds are caked with crystals that promise a
Press release content from Accesswire. The AP news staff was not involved in its creation.
Angle PLC Announces Parsortix-Harvested CTCs Uncover Novel Biomarker
February 18, 2021 GMT
Parsortix system able to harvest difficult-to-detect mesenchymal CTCs
Metastatic biomarker Cyr61 found by researchers in 40% of breast cancer CTCs may be a novel therapeutic target in treating drug-resistant breast cancers
GUILDFORD, SURREY / ACCESSWIRE / February 18, 2021 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the University Medical Centre Hamburg-Eppendorf, Germany, has published new research in the peer reviewed journal Cancers, that demonstrates the ability of the Parsortix® system to harvest circulating tumour cells (CTCs) with a mesenchymal phenotype, which can be used to detect the metastatic biomarker cysteine-rich angiogenetic inducer 61 (Cyr61) in breast cancer patients.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Axogen Sponsored REPOSE℠ Study Completes Pilot Phase Analysis
Axogen, Inc.February 18, 2021 GMT
ALACHUA, Fla., Feb. 18, 2021 (GLOBE NEWSWIRE) Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced completion of pilot phase analysis for its REPOSE clinical study.
Analysis of the REPOSE study’s 15-subject single arm pilot phase demonstrated that subjects experienced a clinically significant reduction in pain from baseline at each of the 3, 6, 9, and 12 month timepoints following surgical excision of the neuroma and placement of Axoguard Nerve Cap® (p 0.0001). Specifically, the study observed a mean reduction in pain of 69 points at 3 months and 80 points at 12 months as measured on the 100-point Visual Analog Scale (VAS). Additionally, subjects experienced clinically m